Focus Wound Healing

Aposcience AG has found that the mixture of active components secreted from cultured apoptotic peripheral white blood cells (PBMCs) has superior efficacy in promoting wound healing and skin regeneration. The products have this effect by stimulating migration of keratinocytes and fibroblasts into the wounded area, as well as by promoting neovascularization of the wound and improving blood and oxygen supply.

The company expects that products derived from PBMCs will have a significant impact in the care for millions of patients who are afflicted by poorly healing wounds (diabetic foot ulcers, ischemic ulcerations, pressure ulcers) and therefore present a very important market opportunity. If efficacy can be demonstrated in clinical trials, a turnover of well over 1 billion Euros can be expected.

Latest News

Approval of DSMB for Lead In-Phase and Go-Ahead for MARSYAS II Main Study



Approval for clinical phase II study in DFU by German health agency PEI